UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 62

Sortiert nach

Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study

Journal of clinical pharmacology, 2019-05, Vol.59 (5), p.702-716

2019

Link zum Volltext

Verfügbarkeit prüfen

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

The lancet oncology, 2017-01, Vol.18 (1), p.52-62

2017

Link zum Volltext

Verfügbarkeit prüfen

Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5153-5159

2009

Link zum Volltext

Verfügbarkeit prüfen

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Breast cancer research : BCR, 2017-02, Vol.19 (1), p.16-16, Article 16

2017

Link zum Volltext

Verfügbarkeit prüfen

Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer

Breast disease, 2010, Vol.32 (1-2), p.35

2010

Link zum Volltext

Verfügbarkeit prüfen

Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer

Cancer epidemiology, biomarkers & prevention, 2008-07, Vol.17 (7), p.1696-1701

2008

Link zum Volltext

Verfügbarkeit prüfen

Current NCI‐sponsored Cooperative Group trials of endocrine therapies in breast cancer

Cancer, 2008-02, Vol.112 (3), p.723-729

2008

Link zum Volltext

Verfügbarkeit prüfen

BRCA1/2 mutations and triple negative breast cancers

Breast disease, 2010, Vol.32 (1-2), p.25

2010

Link zum Volltext

Verfügbarkeit prüfen

Epidemiology of triple negative breast cancers

Breast disease, 2011, Vol.32 (1-2), p.5

2011

Link zum Volltext

Verfügbarkeit prüfen

Gynecologic and hormonal effects of raloxifene in premenopausal women

Fertility and sterility, 2007-12, Vol.88 (6), p.1637-1644

2007

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer

Clinical cancer research, 2004-10, Vol.10 (20), p.6764-6769

2004

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Trial and Pharmacokinetic Study of Tipifarnib, a Farnesyltransferase Inhibitor, and Tamoxifen in Metastatic Breast Cancer

Clinical cancer research, 2005-02, Vol.11 (3), p.1247-1252

2005

Link zum Volltext

Verfügbarkeit prüfen

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

The lancet oncology, 2018-10, Vol.19 (10), p.1372-1384

2018

Link zum Volltext

Verfügbarkeit prüfen

Premenopausal Breast Cancer: Estrogen Receptor Status and Insulin-Like Growth Factor-I (IGF-I), Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3), and Leptin

The breast journal, 2009-07, Vol.15 (4), p.426-428

2009

Link zum Volltext

Verfügbarkeit prüfen

Current treatment options in triple negative breast cancer

Breast disease, 2010, Vol.32 (1-2), p.99

2010

Link zum Volltext

Verfügbarkeit prüfen

Effects of Raloxifene on Circulating Prolactin and Estradiol Levels in Premenopausal Women at High Risk for Developing Breast Cancer

Cancer epidemiology, biomarkers & prevention, 2006-06, Vol.15 (6), p.1153-1158

2006

Link zum Volltext

Verfügbarkeit prüfen

Recruitment to a physical activity intervention study in women at increased risk of breast cancer

BMC medical research methodology, 2009-04, Vol.9 (1), p.27-27, Article 27

2009

Link zum Volltext

Verfügbarkeit prüfen

Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

European journal of cancer (1990), 2018-01, Vol.89, p.27-35

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of Raloxifene on Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Leptin in Premenopausal Women at High Risk for Developing Breast Cancer

Cancer epidemiology, biomarkers & prevention, 2003-12, Vol.12 (12), p.1468-1473

2003

Link zum Volltext

Verfügbarkeit prüfen

Satisfaction with cancer care among underserved racial‐ethnic minorities and lower‐income patients receiving patient navigation

Cancer, 2016-04, Vol.122 (7), p.1060-1067

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinical trials in triple negative breast cancer

Breast disease, 2010, Vol.32 (1-2), p.123

2010

Link zum Volltext

Verfügbarkeit prüfen

Effect of raloxifene on salivary sex steroid concentrations in premenopausal women

Journal of endocrinology, 2006-12, Vol.191 (3), p.599-604

2006

Link zum Volltext

Verfügbarkeit prüfen

BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer

Breast disease, 2010, Vol.32 (1-2), p.85

2010

Link zum Volltext

Verfügbarkeit prüfen

Molecular profiling of triple negative breast cancer

Breast disease, 2010, Vol.32 (1-2), p.73

2010

Link zum Volltext

Verfügbarkeit prüfen

Effect of patient navigation on satisfaction with cancer-related care

Supportive care in cancer, 2016-04, Vol.24 (4), p.1729-1753

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(61)
Tagungsberichte
(1)

Sprache

Englisch
(62)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(45)
Female
(44)
Life Sciences & Biomedicine
(34)
Science & Technology
(34)
Oncology
(29)
Middle Aged
(24)
Adult
(19)
Breast Cancer
(19)
Breast Neoplasms - Pathology
(19)
Breast Neoplasms - Drug Therapy
(18)
Biological And Medical Sciences
(17)
Medical Sciences
(16)
Tumors
(16)
Breast Neoplasms - Metabolism
(14)
Aged
(13)
Receptor, Erbb-2 - Metabolism
(13)
Receptors, Estrogen - Metabolism
(11)
Breast Neoplasms - Genetics
(10)
Gynecology. Andrology. Obstetrics
(10)
Receptors, Progesterone - Metabolism
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer

Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer

Current NCI‐sponsored Cooperative Group trials of endocrine therapies in breast cancer

BRCA1/2 mutations and triple negative breast cancers

Epidemiology of triple negative breast cancers

Gynecologic and hormonal effects of raloxifene in premenopausal women

A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer

A Phase I Trial and Pharmacokinetic Study of Tipifarnib, a Farnesyltransferase Inhibitor, and Tamoxifen in Metastatic Breast Cancer

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

Premenopausal Breast Cancer: Estrogen Receptor Status and Insulin-Like Growth Factor-I (IGF-I), Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3), and Leptin

Current treatment options in triple negative breast cancer

Effects of Raloxifene on Circulating Prolactin and Estradiol Levels in Premenopausal Women at High Risk for Developing Breast Cancer

Recruitment to a physical activity intervention study in women at increased risk of breast cancer

Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

Effect of Raloxifene on Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Leptin in Premenopausal Women at High Risk for Developing Breast Cancer

Satisfaction with cancer care among underserved racial‐ethnic minorities and lower‐income patients receiving patient navigation

Clinical trials in triple negative breast cancer

Effect of raloxifene on salivary sex steroid concentrations in premenopausal women

BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer

Molecular profiling of triple negative breast cancer

Effect of patient navigation on satisfaction with cancer-related care

Suchergebnisse filtern